Zymeworks Inc. (ZYME) Stock
ZYME has an Alpha Score of 47 out of 100 (weak), computed on Nov 9, 2026 from 2 of 4 sub-scores. 3 of the hedge funds AlphaScala tracks reported ZYME in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $23.90M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Nov 10, 2026.
What is ZYME's Alpha Score?
How it works →Alpha Score of 47 reflects weak overall profile with strong momentum, poor quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 9, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own ZYME?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 914K | $23.90M | -21% |
| D.E. Shaw David Shaw | 145K | $3.79M | -39% |
| Marshall Wace | 41K | $1.07M | +27% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Zymeworks Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 9, 26 | Schayowitz Adam | EVP, Head of R&D | SELL | 13.8K | $358K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →What are ZYME's key statistics?
Key statistics as of Nov 1, 2026
How does ZYME's valuation compare with the Healthcare sector?
| Metric | ZYME | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -404.00% | 3.60% | 175 |
| Return on equity | -72.07% | 2.93% | 201 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
ZYME price chart
Powered by TradingViewWhat does Zymeworks Inc. do?
Zymeworks Inc. is a biotechnology company that focuses on innovating biotherapeutics for the treatment of cancer and autoimmune diseases. The company's core mission revolves around developing novel, multifunctional therapeutics with the potential to improve efficacy and reduce side effects compared to conventional cancer treatments. Zymeworks utilizes its proprietary platforms, such as the Azymetric and EFECT technologies, which enable the creation of multifunctional antibody therapeutics. These assets are significant in sectors such as oncology and immunology, addressing unmet needs with therapies aimed at complex and difficult-to-treat conditions. Based in Canada, Zymeworks collaborates with leading global pharmaceutical companies to enhance the reach and impact of its research. In the financial market, Zymeworks Inc. is notable for its strategic partnerships and potential for contributing to advancements in precision medicine, emphasizing its role not only in scientific innovation but also as a key player in the biotech industry's approach to personalized healthcare solutions.